Table 1.

Invitro conditions to evaluate the cytotoxicity of epratuzumab against CD22-expressing B cells

Conditions	Format
Target cells + epratuzumab IgG immobilized onto microtiter wells overnight	Dried-I
Target cells + labetuzumab IgG immobilized onto microtiter wells overnight	Isotype control for Dried-I
Target cells + epratuzumab IgG over a monolayer of HUV-EC	Dried-II
Target cells + labetuzumab IgG over a monolayer of HUV-EC	Isotype control for Dried-II
Target cells + epratuzumab IgG or F(ab’)2 in solution	Wet-I
Target cells + epratuzumab IgG + GAH in solution	Wet-IIA
Target cells + epratuzumab IgG + anti-IgM (1 μg/mL) in solution	Wet-IIB
Target cells + epratuzumab IgG + GAH + anti-IgM (1 μg/mL) in solution	Wet-III
Target cells + epratuzumab IgG conjugated to polystyrene beads	Particulate-I
Target cells + epratuzumab IgG bound to Protein A-Sepharose	Particulate-II
Target cells + anti-IgM (10 μg/mL) in solution	Positive control